thalidomide has been researched along with Colorectal Cancer in 24 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to assess the efficacy and safety of combination treatment with lenalidomide and cetuximab in KRAS-mutant metastatic colorectal cancer patients." | 9.17 | Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. ( Beck, R; Bencardino, K; Elez, ME; Gandhi, A; Jungnelius, U; Li, M; Prenen, H; Romano, A; Sanchis, M; Sartore-Bianchi, A; Shi, T; Siena, S; Tabernero, J; Tejpar, S; Van Cutsem, E, 2013) |
| "This study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients participating in a phase II multicenter, open-label clinical trial receiving lenalidomide alone or lenalidomide plus cetuximab." | 9.17 | Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. ( Chopra, R; Gandhi, AK; Jungnelius, U; Li, M; Romano, A; Schafer, PH; Shi, T; Siena, S; Tabernero, J, 2013) |
| "Irinotecan plus fuorouracil and leucovorin without oral intake of thalidomide is as effective and tolerable as irinotecan plus fuorouracil and leucovorin combined with oral thalidomide for advanced colorectal cancer." | 9.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "This study was designed to estimate the percentage of objective tumor responses, toxicity profile, and obtain additional information about the plasma pharmacokinetics of thalidomide in patients with refractory and progressing metastatic colorectal cancer." | 9.10 | Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. ( Cancela, AI; Costa, TD; Dal Lago, L; Di Leone, LP; Fernandes, SA; Jung, KT; Richter, MF; Rodrigues, AC; Schwartsmann, G, 2003) |
| "Fifteen patients with metastatic colorectal cancer were treated with irinotecan (CPT-11, Camptosar) at 300 to 350 mg/m2 every 21 days and thalidomide (Thalomid) at 400 mg/d." | 9.09 | Irinotecan and thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2000) |
| "A consecutive cohort of pretreated patients with advanced colorectal cancer were treated with thalidomide combined with chemotherapy." | 7.81 | Thalidomide Combined with Chemotherapy in Treating Patients with Advanced Colorectal Cancer. ( Deng, LC; Gu, HG; Gu, M; Huang, XE; Ji, ZQ; Li, L; Liu, MY; Liu, Y; Qian, T; Shen, HL; Wang, L; Yan, XC, 2015) |
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 6.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 6.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| "Thalidomide (Thalomid) has antiangiogenic properties, and angiogenesis has been shown to influence the outcome of colon cancer patients." | 6.41 | Irinotecan/thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2002) |
| "Apremilast did not inhibit the proliferation of HKe3-wtPDE4B2 cells or HKe3-mtKRAS in two-dimensional cultures, whereas the number of apoptotic HKe3-wtPDE4B2 cells and HKe3-mtKRAS cells increased after apremilast treatment in 3DC, leading to formation of a luminal cavity." | 5.46 | Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant ( Baillie, GS; Doi, K; Ishikura, S; Iwaihara, Y; Luo, H; Nishi, K; Sakata, T; Shirasawa, S; Tsunoda, T; Wills, L, 2017) |
| "Lenalidomide is an oral drug with immune-modulatory and anti-angiogenic activity against selected hematologic malignancies but as yet little is known regarding its effectiveness for solid tumors." | 5.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "Thalidomide was administered daily at doses ranging from 50 to 300 mg/kg by intraperitoneal injection." | 5.33 | Effect of thalidomide on colorectal cancer liver metastases in CBA mice. ( Christophi, C; Daruwalla, J; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2005) |
| "This study aimed to assess the efficacy and safety of combination treatment with lenalidomide and cetuximab in KRAS-mutant metastatic colorectal cancer patients." | 5.17 | Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. ( Beck, R; Bencardino, K; Elez, ME; Gandhi, A; Jungnelius, U; Li, M; Prenen, H; Romano, A; Sanchis, M; Sartore-Bianchi, A; Shi, T; Siena, S; Tabernero, J; Tejpar, S; Van Cutsem, E, 2013) |
| "This study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients participating in a phase II multicenter, open-label clinical trial receiving lenalidomide alone or lenalidomide plus cetuximab." | 5.17 | Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. ( Chopra, R; Gandhi, AK; Jungnelius, U; Li, M; Romano, A; Schafer, PH; Shi, T; Siena, S; Tabernero, J, 2013) |
| "Irinotecan plus fuorouracil and leucovorin without oral intake of thalidomide is as effective and tolerable as irinotecan plus fuorouracil and leucovorin combined with oral thalidomide for advanced colorectal cancer." | 5.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "This study was designed to estimate the percentage of objective tumor responses, toxicity profile, and obtain additional information about the plasma pharmacokinetics of thalidomide in patients with refractory and progressing metastatic colorectal cancer." | 5.10 | Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. ( Cancela, AI; Costa, TD; Dal Lago, L; Di Leone, LP; Fernandes, SA; Jung, KT; Richter, MF; Rodrigues, AC; Schwartsmann, G, 2003) |
| "Irinotecan is the only accepted second-line treatment for colorectal cancer in the USA." | 5.09 | Effect of thalidomide on gastrointestinal toxic effects of irinotecan. ( Broadwater, R; Govindarajan, R; Hauer-Jensen, M; Heaton, KM; Lang, NP; Zeitlin, A, 2000) |
| "Fifteen patients with metastatic colorectal cancer were treated with irinotecan (CPT-11, Camptosar) at 300 to 350 mg/m2 every 21 days and thalidomide (Thalomid) at 400 mg/d." | 5.09 | Irinotecan and thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2000) |
| "A consecutive cohort of pretreated patients with advanced colorectal cancer were treated with thalidomide combined with chemotherapy." | 3.81 | Thalidomide Combined with Chemotherapy in Treating Patients with Advanced Colorectal Cancer. ( Deng, LC; Gu, HG; Gu, M; Huang, XE; Ji, ZQ; Li, L; Liu, MY; Liu, Y; Qian, T; Shen, HL; Wang, L; Yan, XC, 2015) |
| " In a heavily pretreated patient with advanced colorectal cancer carrying mutations in APC and KRAS genes, we show an early metabolic response and enhanced NK cell activity to monotherapy with lenalidomide." | 3.80 | Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. ( Amann, A; Auer, T; Gamerith, G; Hilbe, W; Kircher, B; Loeffler-Ragg, J; Putzer, D; Schenk, B; Zwierzina, H, 2014) |
| "Lenalidomide is an immunomodulatory agent with the capacity to stimulate immune cell cytokine production and ADCC activity." | 2.82 | A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. ( Bertino, EM; Carson, WE; Davis, M; Grever, M; McMichael, EL; Mo, X; Otterson, GA; Paul, B; Trikha, P, 2016) |
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 2.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 2.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| "Thalidomide (Thalomid) has antiangiogenic properties, and angiogenesis has been shown to influence the outcome of colon cancer patients." | 2.41 | Irinotecan/thalidomide in metastatic colorectal cancer. ( Govindarajan, R, 2002) |
| "Apremilast did not inhibit the proliferation of HKe3-wtPDE4B2 cells or HKe3-mtKRAS in two-dimensional cultures, whereas the number of apoptotic HKe3-wtPDE4B2 cells and HKe3-mtKRAS cells increased after apremilast treatment in 3DC, leading to formation of a luminal cavity." | 1.46 | Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant ( Baillie, GS; Doi, K; Ishikura, S; Iwaihara, Y; Luo, H; Nishi, K; Sakata, T; Shirasawa, S; Tsunoda, T; Wills, L, 2017) |
| "Lenalidomide is an oral drug with immune-modulatory and anti-angiogenic activity against selected hematologic malignancies but as yet little is known regarding its effectiveness for solid tumors." | 1.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "Hepatic metastasis from colorectal cancer (mCRC) is best treated with a multidisciplinary approach." | 1.35 | Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. ( Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE, 2009) |
| "In addition, an in vivo experimental metastasis model also showed that treatment with the drugs resulted in a significantly lower number of metastatic pulmonary nodules relative to control mice." | 1.35 | Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). ( Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Liu, WM; Meyer, B, 2009) |
| "Thalidomide was administered daily at doses ranging from 50 to 300 mg/kg by intraperitoneal injection." | 1.33 | Effect of thalidomide on colorectal cancer liver metastases in CBA mice. ( Christophi, C; Daruwalla, J; Malcontenti-Wilson, C; Muralidharan, V; Nikfarjam, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (50.00) | 29.6817 |
| 2010's | 11 (45.83) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Kurata, M | 1 |
| Ohyama, M | 1 |
| Nishi, K | 1 |
| Luo, H | 1 |
| Ishikura, S | 1 |
| Doi, K | 1 |
| Iwaihara, Y | 1 |
| Wills, L | 1 |
| Baillie, GS | 1 |
| Sakata, T | 1 |
| Shirasawa, S | 1 |
| Tsunoda, T | 1 |
| Shen, Z | 1 |
| Zhou, R | 1 |
| Liu, C | 1 |
| Wang, Y | 1 |
| Zhan, W | 1 |
| Shao, Z | 1 |
| Liu, J | 1 |
| Zhang, F | 1 |
| Xu, L | 1 |
| Zhou, X | 1 |
| Qi, L | 1 |
| Bo, F | 1 |
| Ding, Y | 1 |
| Zhao, L | 1 |
| Siena, S | 2 |
| Van Cutsem, E | 1 |
| Li, M | 2 |
| Jungnelius, U | 2 |
| Romano, A | 2 |
| Beck, R | 1 |
| Bencardino, K | 1 |
| Elez, ME | 1 |
| Prenen, H | 1 |
| Sanchis, M | 1 |
| Sartore-Bianchi, A | 1 |
| Tejpar, S | 1 |
| Gandhi, A | 1 |
| Shi, T | 2 |
| Tabernero, J | 2 |
| Gandhi, AK | 1 |
| Schafer, PH | 1 |
| Chopra, R | 1 |
| Gamerith, G | 1 |
| Auer, T | 1 |
| Amann, A | 1 |
| Putzer, D | 1 |
| Schenk, B | 1 |
| Kircher, B | 1 |
| Hilbe, W | 1 |
| Zwierzina, H | 1 |
| Loeffler-Ragg, J | 1 |
| Shen, P | 1 |
| Thomas, CR | 1 |
| Fenstermaker, J | 1 |
| Aklilu, M | 1 |
| McCoy, TP | 1 |
| Levine, EA | 1 |
| Huang, XE | 1 |
| Yan, XC | 1 |
| Wang, L | 1 |
| Ji, ZQ | 1 |
| Li, L | 1 |
| Liu, MY | 1 |
| Qian, T | 1 |
| Shen, HL | 1 |
| Gu, HG | 1 |
| Liu, Y | 1 |
| Gu, M | 1 |
| Deng, LC | 1 |
| Said, R | 1 |
| Kakadiaris, E | 1 |
| Piha-Paul, S | 1 |
| Fu, S | 1 |
| Falchook, G | 1 |
| Janku, F | 1 |
| Wheler, JJ | 1 |
| Zinner, R | 1 |
| Hong, DS | 1 |
| Kurzrock, R | 1 |
| Tsimberidou, AM | 1 |
| Leuci, V | 1 |
| Maione, F | 1 |
| Rotolo, R | 1 |
| Giraudo, E | 1 |
| Sassi, F | 1 |
| Migliardi, G | 1 |
| Todorovic, M | 1 |
| Gammaitoni, L | 1 |
| Mesiano, G | 1 |
| Giraudo, L | 1 |
| Luraghi, P | 1 |
| Leone, F | 1 |
| Bussolino, F | 1 |
| Grignani, G | 1 |
| Aglietta, M | 1 |
| Trusolino, L | 1 |
| Bertotti, A | 1 |
| Sangiolo, D | 1 |
| Bertino, EM | 1 |
| McMichael, EL | 1 |
| Mo, X | 1 |
| Trikha, P | 1 |
| Davis, M | 1 |
| Paul, B | 1 |
| Grever, M | 1 |
| Carson, WE | 1 |
| Otterson, GA | 1 |
| Scoggins, CR | 1 |
| Campbell, ML | 1 |
| Landry, CS | 1 |
| Slomiany, BA | 1 |
| Woodall, CE | 1 |
| McMasters, KM | 1 |
| Martin, RC | 1 |
| Liu, WM | 2 |
| Laux, H | 1 |
| Henry, JY | 2 |
| Bolton, TB | 1 |
| Dalgleish, AG | 3 |
| Galustian, C | 2 |
| Meyer, B | 1 |
| Bartlett, JB | 1 |
| Marriott, JB | 1 |
| Clarke, IA | 1 |
| Czajka, A | 1 |
| Dredge, K | 1 |
| Childs, K | 1 |
| Man, HW | 1 |
| Schafer, P | 1 |
| Govinda, S | 1 |
| Muller, GW | 1 |
| Stirling, DI | 1 |
| Dal Lago, L | 1 |
| Richter, MF | 1 |
| Cancela, AI | 1 |
| Fernandes, SA | 1 |
| Jung, KT | 1 |
| Rodrigues, AC | 1 |
| Costa, TD | 1 |
| Di Leone, LP | 1 |
| Schwartsmann, G | 1 |
| Sparano, JA | 1 |
| Gray, R | 1 |
| Giantonio, B | 1 |
| O'Dwyer, P | 1 |
| Comis, RL | 1 |
| Collins, TS | 1 |
| Hurwitz, HI | 1 |
| Daruwalla, J | 1 |
| Nikfarjam, M | 1 |
| Malcontenti-Wilson, C | 1 |
| Muralidharan, V | 1 |
| Christophi, C | 1 |
| McCollum, AD | 1 |
| Wu, B | 1 |
| Clark, JW | 1 |
| Kulke, MH | 1 |
| Enzinger, PC | 1 |
| Ryan, DP | 1 |
| Earle, CC | 1 |
| Michelini, A | 1 |
| Fuchs, CS | 1 |
| Zhang, HG | 1 |
| Li, J | 1 |
| Qin, SK | 1 |
| Zhang, YJ | 1 |
| Song, SP | 1 |
| Chu, DT | 1 |
| Govindarajan, R | 3 |
| Heaton, KM | 1 |
| Broadwater, R | 1 |
| Zeitlin, A | 1 |
| Lang, NP | 1 |
| Hauer-Jensen, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Open-Label Study To Evaluate The Efficacy And Safety Of Lenalidomide In Combination With Cetuximab In Pretreated Subjects With K-Ras Mutant Metastatic Colorectal Cancer[NCT01032291] | Phase 2 | 51 participants (Actual) | Interventional | 2009-12-31 | Terminated (stopped due to A business decision not to continue with Phase 2b based on non-safety observations during proof of concept phase.) | ||
| Phase 1/2 Study of Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors[NCT01166035] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2010-03-31 | Recruiting | ||
| Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients- A Prospective, Randomised, Single Blind, Three Arm, Phase Four Prevention Trial[NCT00772824] | Phase 4 | 23 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The number of participants with DLTs determines the maximum tolerated dose of the combination therapy used in the Proof of Concept (POC) period:~If <2 of the initial 6 participants experience a DLT, then the POC will start with lenalidomide at 25 mg.~If ≥2 of the initial 6 participants experienced a DLT, then 6 more subjects were to be enrolled at 20 mg lenalidomide.~If <2 of the additional 6 subjects experienced a DLT, then the lenalidomide starting dose for the POC was to be 20 mg.~If ≥2 of the additional 6 subjects experienced a DLT, then 6 more subjects were to be enrolled at 15 mg lenalidomide.~If <2 of the additional 6 subjects experienced a DLT, then the POC was to start with lenalidomide at 15 mg.~If ≥2 of the additional 6 subjects experienced a DLT, the dosing for the study was to be reassessed by Celgene Corporation and the investigators." (NCT01032291)
Timeframe: Up to Day 28 (Cycle 1)
| Intervention | participants (Number) |
|---|---|
| Lenalidomide Plus Cetuximab (Safety Lead-in) | 1 |
"Tumor response was evaluated every 2 cycles beginning with Cycle 3 Day 1 and at treatment discontinuation. Response and progression were evaluated using the RECIST 1.1 criteria (Eisenhauer, 2009).~Complete response-disappearance of all lesions~Partial response-30% decrease in the sum of diameters of target lesions from baseline~Stable disease-neither shrinkage nor increase of lesions.~Progressive Disease-20% increase in the sum of diameters of target lesions from nadir.~Participants with evidence of objective tumor response have the response confirmed with repeat assessments performed at the next scheduled scan." (NCT01032291)
Timeframe: Week 9 up to week 24
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Response Not Evaluable | |
| Lenalidomide (Proof of Concept) | 0 | 0 | 3 | 13 | 5 |
| Lenalidomide Plus Cetuximab (Proof of Concept) | 0 | 0 | 5 | 13 | 3 |
TEAEs are any adverse event occurring or worsening on or after the first treatment of any study drug and within 28 days after the last dose of the last study drug received. Relation to study drug was determined by the investigator. Severity of AE is graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 4.0. Severity is a 5-point scale: 3= severe or medically significant but not life-threatening 4=life-threatening, urgent intervention required 5=death related to AE. (NCT01032291)
Timeframe: up to week 28
| Intervention | participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >=1 TEAE | Serious TEAE | TEAE leading to discontinuing lenalidomide | TEAE leading to discontinuing cetuximab | TEAE leading to reduction/interruption of lenalido | TEAE leading to reduction/interruption of cetuxima | TEAE related to lenalidomide | TEAE related to cetuximab | TEAE NCI CTC grade 3 or higher | TEAE NCI CTC grade 3+ related to lenalidomide | TEAE NCI CTC grade 3+ related to cetuximab | Serious TEAE related to lenalidomide | Serious TEAE related to cetuximab | |
| Lenalidomide (Proof of Concept) | 20 | 9 | 7 | NA | 6 | NA | 9 | NA | 13 | 4 | NA | 0 | NA |
| Lenalidomide Plus Cetuximab (Proof of Concept) | 21 | 9 | 5 | 6 | 9 | 7 | 13 | 19 | 12 | 4 | 7 | 2 | 2 |
| Lenalidomide Plus Cetuximab (Safety Lead-In) | 8 | 5 | 3 | 3 | 2 | 1 | 5 | 8 | 4 | 3 | 2 | 2 | 2 |
2 reviews available for thalidomide and Colorectal Cancer
| Article | Year |
|---|---|
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cel | 2005 |
Irinotecan/thalidomide in metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Che | 2002 |
10 trials available for thalidomide and Colorectal Cancer
| Article | Year |
|---|---|
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetu | 2013 |
Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colore | 2013 |
Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Appendiceal Neoplasms; | 2014 |
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2016 |
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.
Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; C | 2016 |
Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Colorectal Neoplasms; Disease Progression; | 2003 |
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2006 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2007 |
Effect of thalidomide on gastrointestinal toxic effects of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2000 |
Irinotecan and thalidomide in metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Che | 2000 |
12 other studies available for thalidomide and Colorectal Cancer
| Article | Year |
|---|---|
Long-term remission of severe nail psoriasis after discontinuation of apremilast in a colorectal cancer survivor.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colorectal Neoplasms; Humans; Psoriasis; Severity of Illnes | 2021 |
Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant
Topics: Animals; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neopla | 2017 |
MicroRNA-105 is involved in TNF-α-related tumor microenvironment enhanced colorectal cancer progression.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Dis | 2017 |
Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.
Topics: Adenomatous Polyposis Coli; Adult; Angiogenesis Inhibitors; Antibody-Dependent Cell Cytotoxicity; An | 2014 |
Thalidomide Combined with Chemotherapy in Treating Patients with Advanced Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2016 |
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2009 |
A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro.
Topics: Animals; Biomarkers; Blotting, Western; Cell Line, Tumor; Cluster Analysis; Colorectal Neoplasms; Fe | 2010 |
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).
Topics: Animals; Antineoplastic Agents; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Cytokines; | 2009 |
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associa | 2003 |
Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; Co | 2004 |
Effect of thalidomide on colorectal cancer liver metastases in CBA mice.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Fibroblast Growth Fact | 2005 |